Comparative in vitro activity of ceftaroline and comparator agents against nosocomial Gram-negative and Gram-positive clinically significant bacterial isolates from patients in a teaching hospital in Kuwait

References

• Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:640–650.
   Web of Science ®Google Scholar
• File TM, Low DE, Eckburg PB, Talbot GH, Friedland HD, Lee J, et al. FOCUS 1: a randomized, double-blind, multicenter, phase III trial of the efficacy and safety of ceftarolne fosfomil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):S19–S32.
   Google Scholar
• Teflaro^TM (Ceftaroline fosami)-clean-labeling text -2010-11-08. Reference ID: 2967472. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001ibi.pdf.
   Google Scholar
• Carreno JJ, Lodise TP. Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE. Infect Dis Ther. 2014;3:123–132.10.1007/s40121-014-0036-8
   PubMedGoogle Scholar
• Mpenge MA, MacGowan AP. Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia. Ther Clin Risk manag. 2015;11:565–579.10.2147/TCRM
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Available from: http://www.who.int/mediacentre/factsheets/fs310/en/
   Google Scholar
• Dryden MS. Complicated skin and soft tissue infections. J Antimicrob Chemother. 2010;65(Suppl 3):S35–S44.
   Google Scholar
• Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009;15:1516–1518.10.3201/eid1509.081228
   PubMed Web of Science ®Google Scholar
• Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis. 2005;11:928–930.10.3201/eid1106.040641
   PubMed Web of Science ®Google Scholar
• Kock R, Becker K, Cookson B, van Gemert-Pijnen JE, Harbarth S, Kluytmans J, et al. Methicillin-resistant Staphylococcus aureus (MRSA): burden of disease and control challenge. Euro Surveill. 2010;15:pii=19688.
   Google Scholar
• Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: ESKAPE! an update from the Infectious diseases society of America. Clin Infect Dis. 2009;48:1–12.10.1086/596722
   PubMed Web of Science ®Google Scholar
• Steed ME, Ryback MJ. Reviews of therapeutics. Pharmacotherapy. 2010;30:375–389.10.1592/phco.30.4.375
   PubMed Web of Science ®Google Scholar
• Cardoso T, Almeida M, Friedman ND, Aragao I, Costa-Pereira A, Sarmento AE, et al. Classification of healthcare-associated infection: a systematic review 10 years after the proposal. BMC Med. 2014;12:40.10.1186/1741-7015-12-40
   PubMed Web of Science ®Google Scholar
• Institute Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing; twenty-sixth informational supplement MI00-S26. Wayne, PA: CLSI; 2016.
   Google Scholar
• https://www.acessdata.fda.gov/drugstatfda_docs/label/2009/021182/so/6161.pdf.
   Google Scholar
• Al Sweih N, Al Hashem G, Jamal W, Rotimi V. National surveillance of antimicrobial susceptibility of CTX-M-positive and -negative clinical isolates of escherichia coli from Kuwait government hospitals. J Chemother. 2010;22:254–248.10.1179/joc.2010.22.4.254
   PubMed Web of Science ®Google Scholar
• Leprince C, Desroches M, Emirian A, Coutureau C, Anais L, Fihman V, et al. Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study. Diag Microbiol Infect Dis. 2015;83:175–182.10.1016/j.diagmicrobio.2015.06.007
   PubMed Web of Science ®Google Scholar
• Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010;54:1670–1677.10.1128/AAC.00019-10
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Flamm RK, Sader HS, Jones RN. Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft tissue infections in Europe (2010). Int J Infect Dis. 2013;41:337–342.
   Google Scholar
• Jones RN, Mendes RE, Sader HS. Ceftaroline activity against pathogens associated with complicated skin and soft structure infections: results from an international surveillance study. J Antimicrob Chemother. 2010;65(Suppl 4):S17–31.
   Google Scholar
• Karlowsky JA, Biedenbach DJ, Bouchillon SK, Iaconis JP, Reiszner E, Sahm DF. In vitro activity of ceftaroline against bacterial pathogens isolated from skin and soft tissue infections in Europe, Russia and Turkey in 2012: results from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme. J Antimicrob Chemother. 2016;71:162–169.10.1093/jac/dkv311
   PubMed Web of Science ®Google Scholar
• Flamm RK, Farrell DJ, Sader HS, Jones RN. Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute skin and skin structure infections in United States medical centers (2010-2012). Diag Microbiol Infect Dis. 2014;78:449–456.10.1016/j.diagmicrobio.2014.01.003
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Flamm RK, Sader HS, Jones RN. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009–2011). Diag Microbiol Infect Dis. 2014;78:442–448.
   Web of Science ®Google Scholar
• Ge Y, Biek D, Talbot GH, Sahm D. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52:3398–3407.10.1128/AAC.00149-08
   PubMed Web of Science ®Google Scholar
• Mendes RE, Tsakris A, Sader HS, Jones RN, Biek D, McGhee P, et al. Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline. J Antimicrob Chemother. 2012;67:1321–1324.10.1093/jac/dks069
   PubMed Web of Science ®Google Scholar
• Strommenger B, Layer F, Klare I, Werner G. Pre-use susceptibility to ceftaroline in clinical staphylococcus aureus isolates from Germany: Is there a non-susceptible pool to be selected? PLoS One. 2015;10:e0125864.10.1371/journal.pone.0125864
   PubMed Web of Science ®Google Scholar
• Flamm RK, Sader HS, Farell DJ, Jones RN. Antimicrobial activity of ceftaroline tested against drug-resistant subsets of streptococcus pneumoniae from U.S. Medical Centers. Antimicrob Agents Chemother. 2014;58:2468–2471.10.1128/AAC.02557-13
   PubMed Web of Science ®Google Scholar
• Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serortypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrob Agents Chemother. 2014;58:4923–4927.10.1128/AAC.02976-14
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Mendes RE, Flamm RK, Jones RN, Sader HS. Ceftaroline activity against multidrug–resistant Streptococcus pneumoniae from U.S. medical centers (2014), and molecular characterization of a single ceftaroline nonsusceptible isolate. Microb Drug Resist. 2016. DOI:10.1089/mdr.2016.0258.
   PubMed Web of Science ®Google Scholar
• Mokaddas EM, Rotimi VO, Albert MJ. Increasing prevalence of antimicrobial resistance in streptococcus pneumoniae in Kuwait: implications for therapy. Microb Drug Resist. 2007;13:227–33.10.1089/mdr.2007.774
   PubMed Web of Science ®Google Scholar
• Brandon M, Dowzicky MJ. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004–2011: results from tigecycline evaluation and surveillance trial. J Clin Microbiol. 2013;51:2371–2378.10.1128/JCM.00157-13
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Castanheira M, Farrell DJ, Flamm RK, Mendes RE, et al. Ceftaroline activity against viridans group streptococci from US hospitals. Diag Microbiol Infect Dis. 2016;84:232–235.10.1016/j.diagmicrobio.2015.10.028
   PubMed Web of Science ®Google Scholar
• Lancaster H, Ready D, Mullany P, Spratt D, Bedi R, Wilson M. Prevalence and identification of tetracycline resistant oral bacteria in children not receiving antibiotic therapy. FEMS Microbiol Lett. 2003;228:99–104.10.1016/S0378-1097(03)00740-7
   PubMed Web of Science ®Google Scholar
• Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob Agents Chemother. 1996;40:891–894.
   PubMed Web of Science ®Google Scholar
• Teng LJ, Hsueh PR, Chen YC, Ho SW, Luh KT. Antimicrobial susceptibility of Viridans group streptococci in Taiwan with an emphasis on high rates of resistance to penicillin and macrolides in Streptococcus oralis. J Antimicrob Chemother. 1998;41:621–627.10.1093/jac/41.6.621
   PubMed Web of Science ®Google Scholar
• Rotimi VO, Salako NO, Mokaddas E, Philip L, Rajan P. High frequency of isolation of antibiotic-resistant oral viridans streptococci from children in Kuwait. J Chemother. 2005;17:493–501.10.1179/joc.2005.17.5.493
   PubMed Web of Science ®Google Scholar
• Konig A, Reinert RR, Hakenbeck R. Streptococcus mitis with unusual high level resistance to beta-lactam antibiotics. Micro Drug Resist. 1998;4:45–49.10.1089/mdr.1998.4.45
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, James D, Woodford N. Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint. J Antimicrob Chemother. 2015;70:3259–3266.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Mushtaq S. Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and –resistant pneumococci. Int J Antimicrob Agents. 2014;43:131–134.10.1016/j.ijantimicag.2013.10.016
   PubMed Web of Science ®Google Scholar
• Flamm RK, Sader HS, Farrell DJ, Jones RN. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program. Antimicrob Agents Chemother. 2012;56:2933–2940.10.1128/AAC.00330-12
   PubMed Web of Science ®Google Scholar